Validity of the Cancer and Aging Research Group Predictive Tool in Older Japanese Patients

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 May 14

PMID 35565205

Authors

Hirotaka Suto

Yumiko Inui

Atsuo Okamura

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to evaluate the usefulness of the Cancer and Aging Research Group (CARG) predictive tool in older Japanese patients with cancer. Methods: Patients aged 65 years or older with solid tumors treated with new anticancer regimens in Kakogawa Central City Hospital between April 2016 and March 2019 were included. Grade 3 or higher risks of developing chemotherapy-related adverse events (CRAEs) were calculated using the tool (low-, intermediate-, or high-risk scores). The association between grade 3−5 CRAE incidence during the first course of each regimen and the calculated risk or the patient characteristics was evaluated. The difference in the incidences of CRAEs between the groups was evaluated by Fisher’s exact test. Results: This study examined 76 patients (mean age: 71 (65−82) years). The incidence of grade 3−5 CRAE was 38%, 55%, and 76% in patients classified as low, medium, and high CARG risk scores (p = 0.035), and the incidence of severe non-hematological toxicities was 4%, 31%, and 52% (p < 0.01), respectively. Eastern Cooperative Oncology Group performance status and age were not associated with chemotherapy toxicity. Conclusions: The CARG predictive tool was valid, suggesting its usefulness in optimizing chemotherapy outcomes in older patients with cancer.

Citing Articles

Geriatric assessment for the practicing clinician: The why, what, and how.

Magnuson A, Loh K, Stauffer F, Dale W, Gilmore N, Kadambi S CA Cancer J Clin. 2024; 74(6):496-518.

PMID: 39207229 PMC: 11848937. DOI: 10.3322/caac.21864.

Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol.

Martinez F, Taramasco C, Espinoza M, Acevedo J, Goic C, Nervi B Diagnostics (Basel). 2024; 14(6).

PMID: 38535039 PMC: 10968981. DOI: 10.3390/diagnostics14060619.

Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer.

Ramoni D, Coco S, Rossi G, Dellepiane C, Bennicelli E, Santamaria S Lung. 2024; 202(2):197-210.

PMID: 38480620 PMC: 11009777. DOI: 10.1007/s00408-024-00675-5.

Predicting Risk of Severe Toxicity and Early Death in Older Adult Patients Treated with Chemotherapy.

Feliu J, Custodio A, Pinto-Marin A, Higuera O, Perez-Gonzalez M, Del Pino L Cancers (Basel). 2023; 15(18).

PMID: 37760638 PMC: 10526243. DOI: 10.3390/cancers15184670.

Frailty and Cancer: Current Perspectives on Assessment and Monitoring.

Goede V Clin Interv Aging. 2023; 18:505-521.

PMID: 37013130 PMC: 10066705. DOI: 10.2147/CIA.S365494.

References

Muss H, Berry D, Cirrincione C, Budman D, Henderson I, Citron M . Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007; 25(24):3699-704. DOI: 10.1200/JCO.2007.10.9710. View

Nie X, Liu D, Li Q, Bai C . Predicting chemotherapy toxicity in older adults with lung cancer. J Geriatr Oncol. 2014; 4(4):334-9. DOI: 10.1016/j.jgo.2013.05.002. View

Garcia M, Agar M, Soo W, To T, Phillips J . Screening Tools for Identifying Older Adults With Cancer Who May Benefit From a Geriatric Assessment: A Systematic Review. JAMA Oncol. 2021; 7(4):616-627. DOI: 10.1001/jamaoncol.2020.6736. View

Kilpatrick K, Shaw J, Jaramillo R, Toler A, Eisen M, Sangare L . Occurrence and Management of Thrombocytopenia in Metastatic Colorectal Cancer Patients Receiving Chemotherapy: Secondary Analysis of Data From Prospective Clinical Trials. Clin Colorectal Cancer. 2020; 20(2):170-176. DOI: 10.1016/j.clcc.2020.10.004. View

Extermann M, Boler I, Reich R, Lyman G, Brown R, DeFelice J . Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2011; 118(13):3377-86. DOI: 10.1002/cncr.26646. View

Mohile S, Dale W, Somerfield M, Schonberg M, Boyd C, Burhenn P . Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018; 36(22):2326-2347. PMC: 6063790. DOI: 10.1200/JCO.2018.78.8687. View

Hurria A, Hurria A, Brogan K, Panageas K, Pearce C, Norton L . Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging. 2005; 22(9):785-91. DOI: 10.2165/00002512-200522090-00007. View

Zhang J, Liao X, Feng J, Yin T, Liang Y . Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology. Oncol Lett. 2019; 18(5):4947-4955. PMC: 6781512. DOI: 10.3892/ol.2019.10840. View

Yoshida H, Shintani D, Kawashima N, Fujiwara K . Predicting toxicity of platinum and taxane-based chemotherapy in older patients with gynecologic cancer. J BUON. 2020; 25(2):736-742. View

10.

Abbasi J . Older Patients (Still) Left Out of Cancer Clinical Trials. JAMA. 2019; 322(18):1751-1753. DOI: 10.1001/jama.2019.17016. View

11.

Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M . REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2019; 55(1):113-122. PMC: 6942573. DOI: 10.1007/s00535-019-01642-1. View

12.

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D . Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(11):1077-1085. DOI: 10.1016/S1470-2045(13)70154-2. View

13.

Ben Ayed W, Ben Said A, Hamdi A, Mokrani A, Masmoudi Y, Toukabri I . Toxicity, risk factors and management of cisplatin-induced toxicity: A prospective study. J Oncol Pharm Pract. 2020; 26(7):1621-1629. DOI: 10.1177/1078155219901305. View

14.

Chatta G, Price T, Stratton J, Dale D . Aging and marrow neutrophil reserves. J Am Geriatr Soc. 1994; 42(1):77-81. DOI: 10.1111/j.1532-5415.1994.tb06077.x. View

15.

Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H . Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015; 45(9):884-91. DOI: 10.1093/jjco/hyv088. View

16.

Kumar A, Soares H, Balducci L, Djulbegovic B . Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007; 25(10):1272-6. DOI: 10.1200/JCO.2006.09.2759. View

17.

Williams G, MacKenzie A, Magnuson A, Olin R, Chapman A, Mohile S . Comorbidity in older adults with cancer. J Geriatr Oncol. 2016; 7(4):249-57. PMC: 4917479. DOI: 10.1016/j.jgo.2015.12.002. View

18.

Ortland I, Mendel Ott M, Kowar M, Sippel C, Jaehde U, Jacobs A . Comparing the performance of the CARG and the CRASH score for predicting toxicity in older patients with cancer. J Geriatr Oncol. 2020; 11(6):997-1005. DOI: 10.1016/j.jgo.2019.12.016. View

19.

Park K, Kim J, Cho E, Kang J, Shih J, Zimmermann A . East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based.... Cancer Res Treat. 2016; 48(4):1177-1186. PMC: 5080808. DOI: 10.4143/crt.2015.401. View

20.

Ling W, Lee S . Inter-ethnic differences--how important is it in cancer treatment?. Ann Acad Med Singap. 2011; 40(8):356-61. View